HSIC
Henry Schein, Inc.77.05
-0.34-0.44%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Reaffirms momentum, H2-weighted benefits.
Q&A largely reaffirmed prepared remarks on Q4 momentum and 2026 guidance, but stressed value creation benefits ramping in H2 for net full-year positivity amid early investments. Dental markets stable to positive with equipment order backlog extending into Q1, crediting sales execution post-cyber recovery. Implant growth driven by mix shift to faster value brands like S.I.N.—now launching in U.S.—with stable pricing; specialties eyed at 5-8% long-term despite softer U.S. market. Margins pressured by value implant mix but aided by private labels. Medical volumes steady despite respiratory dip. Management confident. Watch H2 earnings acceleration.
Key Stats
Market Cap
9.34BP/E (TTM)
24.31Basic EPS (TTM)
3.17Dividend Yield
0%Recent Filings
10-K
FY2025 10-K filing
Henry Schein filed its 10-K for FY2025 ended December 27, 2025, but financial statements and MD&A with topline, profitability, or quarterly results not disclosed in the provided filing. Exhibits detail executive employment agreements, including a 2023 offer for CEO, International Distribution Group, Global Dental Equipment and Lab, with $575,000 base, $402,500 target bonus, $900,000 annual LTI, $750,000 sign-on equity, and $1.5M relocation bonus over 48 months. A restrictive covenant agreement imposes 18-month global non-compete post-separation. SERP amendment clarifies 'Recognized Compensation' per Code Section 401(a)(17). No Q4 metrics or momentum available. Key risk: intense competition could erode market share.
8-K
Q4 sales soar 7.7%
8-K
Lowery named HSIC CEO
Henry Schein appointed Frederick Lowery as CEO effective March 2, 2026, succeeding Stanley Bergman, who stays on as Chairman. Lowery, ex-Thermo Fisher EVP with 20+ years in healthcare distribution, gets $1.25M base, 150% target bonus, $10M 2026 equity, $2.5M sign-on RSUs, and $1.184M cash bonus. Bylaws amended to allow standalone CEO. Smooth transition planned.
8-K
Extended shelf facilities to 2028
Henry Schein amended its private shelf agreements with Prudential, New York Life, MetLife, and Corebridge on December 19, 2025, extending facility termination dates to December 19, 2028 while tweaking financial covenants. This bolsters debt access. Amendments create new obligations. Details in exhibits.
8-K
CEO successor by mid-January
Henry Schein expects to name its next CEO by mid-January 2026, with Stanley M. Bergman staying on as CEO and Chairman until then. A letter agreement extends his employment through the successor's start or 30 days after his notice, maintaining his base salary and pro-rated bonus. Bergman ensures smooth transition. Leadership continuity holds amid search.
IPO
Website
Employees
Sector
Industry
CAH
Cardinal Health, Inc.
197.89-2.07
COR
Cencora, Inc.
341.72-8.60
EBOSF
EBOS GROUP
23.75+0.00
HCSG
Healthcare Services Group, Inc.
19.09-0.27
HLYK
HealthLynked Corp.
1.67-0.22
MCK
McKesson Corporation
809.96-13.05
MHUA
Meihua International Medical Te
7.61-6.41
OMI
Owens & Minor, Inc.
3.10+0.09
XRAY
DENTSPLY SIRONA Inc.
11.37-0.03
ZIMV
ZimVie Inc.
18.99+0.00